AU2018283348A1 - IL-10, S100B and H-FABP markers and their use in detecting traumatic brain injury - Google Patents

IL-10, S100B and H-FABP markers and their use in detecting traumatic brain injury Download PDF

Info

Publication number
AU2018283348A1
AU2018283348A1 AU2018283348A AU2018283348A AU2018283348A1 AU 2018283348 A1 AU2018283348 A1 AU 2018283348A1 AU 2018283348 A AU2018283348 A AU 2018283348A AU 2018283348 A AU2018283348 A AU 2018283348A AU 2018283348 A1 AU2018283348 A1 AU 2018283348A1
Authority
AU
Australia
Prior art keywords
markers
tbi
protein
fabp
mtbi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018283348A
Other languages
English (en)
Inventor
Jean-Charles Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Geneve
Original Assignee
Universite de Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Geneve filed Critical Universite de Geneve
Publication of AU2018283348A1 publication Critical patent/AU2018283348A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2018283348A 2017-06-15 2018-06-07 IL-10, S100B and H-FABP markers and their use in detecting traumatic brain injury Abandoned AU2018283348A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17001015 2017-06-15
EP17001015.1 2017-06-15
PCT/EP2018/065090 WO2018228927A1 (en) 2017-06-15 2018-06-07 Il-10, s100b and h-fabp markers and their use in detecting traumatic brain injury

Publications (1)

Publication Number Publication Date
AU2018283348A1 true AU2018283348A1 (en) 2020-01-02

Family

ID=59091305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018283348A Abandoned AU2018283348A1 (en) 2017-06-15 2018-06-07 IL-10, S100B and H-FABP markers and their use in detecting traumatic brain injury

Country Status (6)

Country Link
US (1) US20200174015A1 (enExample)
EP (1) EP3639034A1 (enExample)
JP (1) JP2020525765A (enExample)
CN (1) CN110770586A (enExample)
AU (1) AU2018283348A1 (enExample)
WO (1) WO2018228927A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157206A1 (en) * 2019-01-31 2020-08-06 University Of Geneva Prospective markers in traumatic brain injury (tbi)
CN115170540B (zh) * 2022-07-26 2025-07-11 浙江工业大学 一种基于多模态影像特征融合的轻度创伤性脑损伤分类方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008819A2 (en) * 2006-07-11 2008-01-17 University Of Florida Research Foundation, Inc. Diagnosis and treatment of neurological inflammation
US20120322682A1 (en) * 2011-06-20 2012-12-20 William Marsh Rice University Brain injury biomarker panel
US20170023591A1 (en) * 2014-04-07 2017-01-26 Iron Horse Diagnostics, Inc. Traumatic Brain Injury and Neurodegenerative Biomarkers, Methods, and Systems
US20180238907A1 (en) * 2014-10-06 2018-08-23 Université de Genéve Markers and their use in brain injury

Also Published As

Publication number Publication date
JP2020525765A (ja) 2020-08-27
US20200174015A1 (en) 2020-06-04
EP3639034A1 (en) 2020-04-22
WO2018228927A1 (en) 2018-12-20
CN110770586A (zh) 2020-02-07

Similar Documents

Publication Publication Date Title
US20200110100A1 (en) Markers and their use in brain injury
Mahan et al. Glial fibrillary acidic protein (GFAP) outperforms S100 calcium-binding protein B (S100B) and ubiquitin C-terminal hydrolase L1 (UCH-L1) as predictor for positive computed tomography of the head in trauma subjects
US12422442B2 (en) Markers and their use in brain injury
Chabok et al. Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury
US20120149042A1 (en) Methods for predicting outcome in traumatic brain injury
Whistler et al. Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome
Wang et al. Evaluation of serum matrix metalloproteinase-3 as a biomarker for diagnosis of epilepsy
Pandey et al. A prospective pilot study on serum cleaved tau protein as a neurological marker in severe traumatic brain injury
Aydın et al. Diagnostic value of serum glial fibrillary acidic protein and S100B serum levels in emergency medicine patients with traumatic versus nontraumatic intracerebral hemorrhage
Zhou et al. Diagnostic and Predictive Value of Novel inflammatory markers of the severity of Acute traumatic spinal cord Injury: a retrospective study
Bogaardt et al. Cognitive impairment, fatigue and depression in multiple sclerosis: Is there a difference between benign and non-benign MS?
KR20180083909A (ko) 알츠하이머병의 진단 또는 예측, 또는 파킨슨병의 진단을 위한 락토페린
WO2020110143A1 (en) Methods, systems, and a kit for diagnosis, detection, monitoring and treatment of traumatic brain injury
US20200174015A1 (en) Il-10, s100b and h-fabp markers and their use in detecting traumatic brain injury
Puravet et al. Can the Association of the Biomarkers GFAP and UCH-L1 Predict Intracranial Injury After Mild Traumatic Brain Injury in Adults? A Systematic Review and Meta-Analysis
Stejskal et al. DETERMINATION OF SERUM VISININ LIKE PROTEIN-1 AND ITS POTENTIAL FOR THE DIAGNOSIS OF BRAIN INJURY DUE TO THE STROKE-A PILOT STUDY.
US20110236917A1 (en) Diagnosis of Alzheimer's Disease
EP3918336A1 (en) Prospective markers in traumatic brain injury (tbi)
Goldstein et al. The Pittsburgh Initial Neuropsychological Testing System (PINTS): A neuropsychological screening battery for psychiatric patients
Li et al. Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders
Waliullah et al. Serum S100-Beta as a Biomarker for Neurological Recovery in Acute Spinal Cord Injury (ASCI): A Prospective Case-Control Study
Fakharian et al. A study on the predictive value of glial fibrillary acidic protein for prediction of traumatic brain injury severity
GALHOM et al. Serum S100 Protein as a Predictor of Long Term Outcome in Mild and Moderate Traumatic Brain Injury
Diaz-Arrastia et al. Frederick K. Korley, MD, PhD
Gobergs et al. THE PROGNOSTIC VALUE OF GLASGOW COMA SCALE FOLLOWING TRAUMATIC BRAIN INJURY IN PAEDIATRIC PATIENTS

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application